{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:56:07Z","timestamp":1782496567206,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,26]]},"DOI":"10.7759\/cureus.111573","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:45:06Z","timestamp":1782495906000},"source":"Crossref","is-referenced-by-count":0,"title":["Optimized Oral Glutamatergic Augmentation in Refractory Home-Dominant Contamination Obsessive-Compulsive Disorder With Somatic, Affective, and Motivational Features: A Case Report of Incremental Functional Gains"],"prefix":"10.7759","author":[{"given":"Hoi Ki","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngo","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.2200","article-title":"Obsessive-compulsive disorder: advances in diagnosis and treatment","volume":"317","author":"Hirschtritt ME","year":"2017","unstructured":"Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-compulsive disorder: advances in diagnosis and treatment. JAMA. 2017, 317:1358-67. 10.1001\/jama.2017.2200","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0102-3","article-title":"Obsessive-compulsive disorder","volume":"5","author":"Stein DJ","year":"2019","unstructured":"Stein DJ, Costa DL, Lochner C, et al.. Obsessive-compulsive disorder. Nat Rev Dis Primers. 2019, 5:52. 10.1038\/s41572-019-0102-3","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2009.50","article-title":"Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder","volume":"15","author":"Bloch MH","year":"2010","unstructured":"Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2010, 15:850-5. 10.1038\/mp.2009.50","journal-title":"Mol Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyv047","article-title":"Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"18","author":"Dold M","year":"2015","unstructured":"Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol. 2015, 18:047. 10.1093\/ijnp\/pyv047","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.1932","article-title":"Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial","volume":"70","author":"Simpson HB","year":"2013","unstructured":"Simpson HB, Foa EB, Liebowitz MR, et al.. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry. 2013, 70:1190-9. 10.1001\/jamapsychiatry.2013.1932","journal-title":"JAMA Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1586\/ern.11.200","article-title":"Family accommodation in obsessive-compulsive disorder","volume":"12","author":"Lebowitz ER","year":"2012","unstructured":"Lebowitz ER, Panza KE, Su J, Bloch MH. Family accommodation in obsessive-compulsive disorder. Expert Rev Neurother. 2012, 12:229-38. 10.1586\/ern.11.200","journal-title":"Expert Rev Neurother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2011.03.002","article-title":"The role of avoidance in the phenomenology of obsessive-compulsive disorder","volume":"53","author":"McGuire JF","year":"2012","unstructured":"McGuire JF, Storch EA, Lewin AB, Price LH, Rasmussen SA, Goodman WK. The role of avoidance in the phenomenology of obsessive-compulsive disorder. Compr Psychiatry. 2012, 53:187-94. 10.1016\/j.comppsych.2011.03.002","journal-title":"Compr Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tics.2011.11.003","article-title":"Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways","volume":"16","author":"Milad MR","year":"2012","unstructured":"Milad MR, Rauch SL. Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn Sci. 2012, 16:43-51. 10.1016\/j.tics.2011.11.003","journal-title":"Trends Cogn Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2011.09.006","article-title":"Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment","volume":"132","author":"Pittenger C","year":"2011","unstructured":"Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther. 2011, 132:314-32. 10.1016\/j.pharmthera.2011.09.006","journal-title":"Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept","volume":"38","author":"Rodriguez CI","year":"2013","unstructured":"Rodriguez CI, Kegeles LS, Levinson A, et al.. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology. 2013, 38:2475-83. 10.1038\/npp.2013.150","journal-title":"Neuropsychopharmacology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2011.05.035","article-title":"Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression","volume":"224","author":"Koike H","year":"2011","unstructured":"Koike H, Iijima M, Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res. 2011, 224:107-11. 10.1016\/j.bbr.2011.05.035","journal-title":"Behav Brain Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li N","year":"2010","unstructured":"Li N, Lee B, Liu RJ, et al.. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010, 329:959-64. 10.1126\/science.1190287","journal-title":"Science"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos P","year":"2016","unstructured":"Zanos P, Moaddel R, Morris PJ, et al.. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016, 533:481-6. 10.1038\/nature17998","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2026.1751605","article-title":"DXM, CYP2D6-inhibiting antidepressants, piracetam, and glutamine: proposing a ketamine-class antidepressant regimen with existing drugs","volume":"17","author":"Cheung N","year":"2026","unstructured":"Cheung N. DXM, CYP2D6-inhibiting antidepressants, piracetam, and glutamine: proposing a ketamine-class antidepressant regimen with existing drugs. Front Psychiatry. 2026, 17:1751605. 10.3389\/fpsyt.2026.1751605","journal-title":"Front Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202511.2223.v1","article-title":"Case series: marked improvement in treatment-resistant obsessive-compulsive symptoms with over-the-counter glutamatergic augmentation in routine clinical practice (Preprint)","author":"Cheung N","year":"2025","unstructured":"Cheung N. Case series: marked improvement in treatment-resistant obsessive-compulsive symptoms with over-the-counter glutamatergic augmentation in routine clinical practice (Preprint). Preprints.org. 2025, 10.20944\/preprints202511.2223.v1","journal-title":"Preprints.org"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202512.0185.v1","article-title":"Cheung\u2019s regimen series: successful conversion from one dose of esketamine to a low-cost oral ketamine-class glutamatergic regimen in treatment-resistant depression and OCD (Preprint)","author":"Cheung N","year":"2025","unstructured":"Cheung N. Cheung\u2019s regimen series: successful conversion from one dose of esketamine to a low-cost oral ketamine-class glutamatergic regimen in treatment-resistant depression and OCD (Preprint). Preprints.org. 2025, 10.20944\/preprints202512.0185.v1","journal-title":"Preprints.org"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202511.2246.v1","article-title":"Clinical experience and optimisation of the Cheung glutamatergic regimen for refractory psychiatric diseases (Preprint)","author":"Cheung N","year":"2025","unstructured":"Cheung N. Clinical experience and optimisation of the Cheung glutamatergic regimen for refractory psychiatric diseases (Preprint). Preprints.org. 2025, 10.20944\/preprints202511.2246.v1","journal-title":"Preprints.org"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202512.0585.v1","article-title":"Dosing schedules for dextromethorphan and piracetam in OCD: a case series on diurnal symptom patterns and split-dosing strategies (Preprint)","author":"Cheung N","year":"2025","unstructured":"Cheung N. Dosing schedules for dextromethorphan and piracetam in OCD: a case series on diurnal symptom patterns and split-dosing strategies (Preprint). Preprints.org. 2025, 10.20944\/preprints202512.0585.v1","journal-title":"Preprints.org"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04134.x","article-title":"The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes","volume":"34","author":"Crewe HK","year":"1992","unstructured":"Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 1992, 34:262-5. 10.1111\/j.1365-2125.1992.tb04134.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.23.1081","article-title":"Dextromethorphan-bupropion (Auvelity) for the treatment of major depressive disorder","volume":"21","author":"McCarthy B","year":"2023","unstructured":"McCarthy B, Bunn H, Santalucia M, Wilmouth C, Muzyk A, Smith CM. Dextromethorphan-bupropion (Auvelity) for the treatment of major depressive disorder. Clin Psychopharmacol Neurosci. 2023, 21:609-16. 10.9758\/cpn.23.1081","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2016.11.007","article-title":"In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation","volume":"123","author":"Sager JE","year":"2017","unstructured":"Sager JE, Tripathy S, Price LS, Nath A, Chang J, Stephenson-Famy A, Isoherranen N. In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. Biochem Pharmacol. 2017, 123:85-96. 10.1016\/j.bcp.2016.11.007","journal-title":"Biochem Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/nu12040910","article-title":"Glutamine supplementation prevents chronic stress-induced mild cognitive impairment","volume":"12","author":"Baek JH","year":"2020","unstructured":"Baek JH, Jung S, Son H, Kang JS, Kim HJ. Glutamine supplementation prevents chronic stress-induced mild cognitive impairment. Nutrients. 2020, 12:910. 10.3390\/nu12040910","journal-title":"Nutrients"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.09.040","article-title":"Glutamine has antidepressive effects through increments of glutamate and glutamine levels and glutamatergic activity in the medial prefrontal cortex","volume":"143","author":"Son H","year":"2018","unstructured":"Son H, Baek JH, Go BS, et al.. Glutamine has antidepressive effects through increments of glutamate and glutamine levels and glutamatergic activity in the medial prefrontal cortex. Neuropharmacology. 2018, 143:143-52. 10.1016\/j.neuropharm.2018.09.040","journal-title":"Neuropharmacology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms","volume":"125","author":"Reynolds GP","year":"2010","unstructured":"Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms. Pharmacol Ther. 2010, 125:169-79. 10.1016\/j.pharmthera.2009.10.010","journal-title":"Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-221486","article-title":"Serotonin syndrome caused by drug to drug interaction between escitalopram and dextromethorphan","volume":"2017","author":"Dy P","year":"2017","unstructured":"Dy P, Arcega V, Ghali W, Wolfe W. Serotonin syndrome caused by drug to drug interaction between escitalopram and dextromethorphan. BMJ Case Rep. 2017, 2017:2017221486. 10.1136\/bcr-2017-221486","journal-title":"BMJ Case Rep"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1021\/jm901905j","article-title":"Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors","volume":"53","author":"Ahmed AH","year":"2010","unstructured":"Ahmed AH, Oswald RE. Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors. J Med Chem. 2010, 53:2197-203. 10.1021\/jm901905j","journal-title":"J Med Chem"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2005.tb00268.x","article-title":"Piracetam: a review of pharmacological properties and clinical uses","volume":"11","author":"Winblad B","year":"2005","unstructured":"Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005, 11:169-82. 10.1111\/j.1527-3458.2005.tb00268.x","journal-title":"CNS Drug Rev"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2018.20.1\/phenningsen","article-title":"Management of somatic symptom disorder","volume":"20","author":"Henningsen P","year":"2018","unstructured":"Henningsen P. Management of somatic symptom disorder. Dialogues Clin Neurosci. 2018, 20:23-31. 10.31887\/DCNS.2018.20.1\/phenningsen","journal-title":"Dialogues Clin Neurosci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202511.2067.v1","article-title":"OTC glutamatergic augmentation resolves adolescent refractory somatic symptoms (Preprint)","author":"Cheung N","year":"2025","unstructured":"Cheung N. OTC glutamatergic augmentation resolves adolescent refractory somatic symptoms (Preprint). Preprints.org. 2025, 10.20944\/preprints202511.2067.v1","journal-title":"Preprints.org"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.20944\/preprints202512.0676.v1","article-title":"Rapid remission of refractory hypochondriacal OCD in an elderly patient under glutamatergic augmentation: a high-resolution case observation (Preprint)","author":"Cheung N","year":"2025","unstructured":"Cheung N. Rapid remission of refractory hypochondriacal OCD in an elderly patient under glutamatergic augmentation: a high-resolution case observation (Preprint). Preprints.org. 2025, 10.20944\/preprints202512.0676.v1","journal-title":"Preprints.org"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/508766-optimized-oral-glutamatergic-augmentation-in-refractory-home-dominant-contamination-obsessive-compulsive-disorder-with-somatic-affective-and-motivational-features-a-case-report-of-incremental-functional-gains","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:45:07Z","timestamp":1782495907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/508766-optimized-oral-glutamatergic-augmentation-in-refractory-home-dominant-contamination-obsessive-compulsive-disorder-with-somatic-affective-and-motivational-features-a-case-report-of-incremental-functional-gains"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.111573","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,26]]}}}